Delivery Order SPE2DR25D2216-SPE2DR26F7TX4
- Not listed
- The Defense Logistics Agency awarded a $7,684.68 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml). This competitively awarded, firm fixed-price contract is classified as a child delivery order without set-aside designation and is scheduled for completion by June 3, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 26, 2025, with completion scheduled for August 27, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $11,468.93 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a completion date of August 12, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The vendor will perform this work from its corporate office in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $12,257.90 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Dupixent 300 mg/2 ml pen injections valued at $10,573.44 with an ultimate completion date of November 10, 2025. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $14,337.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on November 10, 2025, with an ultimate completion date of November 12, 2025. This is a non-set-aside award representing a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $4,602.67 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation and specifies October 28, 2025,...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a delivery order valued at $14,595.53 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on October 30, 2025, with an ultimate completion date of October 31, 2025. This non-competitive, firm fixed-price delivery order will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- SPE2DR25D2216Indefinite Delivery Contract
- SPE2DR25D2216-SPE2DR26F7TX4Delivery Order
The Defense Logistics Agency awarded a $14,957.91 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors (2 ml units). This non-competitive delivery order represents a continuation of AmerisourceBergen's extensive role as a pharmaceutical supplier to the federal government. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract is scheduled for completion by November 17, 2025, indicating a rapid fulfillment timeline typical of delivery orders under larger indefinite delivery contracts. This delivery order operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, and medical supplies to military healthcare programs worldwide. Dupixent, a specialty biologic medication used for conditions including atopic dermatitis and asthma, represents the type of specialized pharmaceutical product that falls within the scope of the broader contract vehicle supporting Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 11/14/25 |